Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ESAs In Renal Disease: Risk/Benefit Differs With Disease Stage, Amgen Says

Executive Summary

Medicare coverage policy for erythropoiesis-stimulating agents in patients with chronic kidney disease should recognize that the ESA needs of patients are very different for those who are on dialysis versus those who are not, Amgen said in recent comments to the Centers for Medicare and Medicaid Services
Advertisement

Related Content

Delaying Inclusion Of Oral-Only ESRD Drugs In Bundled Payment Gives Short-Term Reprieve To Genzyme, Amgen
Delaying Inclusion Of Oral-Only ESRD Drugs In Bundled Payment Gives Short-Term Reprieve To Genzyme, Amgen
MedCAC Review Of ESAs In Renal Disease To Help Determine Need For NCD
ESAs In Renal Use May Face New FDA, CMS Constraints; REMS Still In Progress

Topics

Advertisement
UsernamePublicRestriction

Register

PS052455

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel